Ultrasensitive Detection of Cancer with 3D Nano-engineered Microfluidic Chip

University of Kansas Background
Early diagnosis of cancer is the most important factor in successful treatment however current methods of detection allow for only 20% of ovarian cancers to be detected at a stage early enough for treatment. The disclosed technology utilizes 3D printing of nanochips with the capability to detect exosomes in the blood and be a new method for the early diagnosis of many cancers.
Technology Overview
The nanochip is printed using a novel 3D printing technique that is simple and efficient. The inventors have demonstrated their technology can detect MMP14 in circulating exosomes in the blood for detecting cancer at various stages. This diagnostic method requires only a blood sample in order to analyze and detect exosome levels in a patient.
Benefits
Early detection of cancer is the most critical factor for successful treatment. There are very few current diagnostic tests approved by the FDA that have the capability to accurately detect early stages on the disease. This technology has the potential to detect cancer at such an early stage it could lessen the burden of cancer on patients and the economy.
This exosome detecting diagnostic nanochip overcomes current similar technologies. It requires a novel, simple, and efficient 3D printing technique compared to the complex technique currently being used. The invention requires a significantly smaller blood sample because it has enhanced detection capabilities. It also has the capability of being easily mass manufactured.
Applications
This technology is a 3D printed nanochip for exosome detection and analysis. Exosomes have been linked to ovarian, lung, breast, and other cancers and may be a source for biomarkers and early detection. The cancer diagnostic market is a nearly $150 billion industry only expect to grow. The exosome diagnostic sub-market is a newly emerging industry expected to exceed $2.3 billion in the next decade.